Brown David W, Shepard David, Giles Wayne H, Greenlund Kurt J, Croft Janet B
Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA.
Ethn Dis. 2005 Autumn;15(4):620-6.
Regular aspirin use, particularly as secondary prevention, reduces morbidity from heart disease and stroke. Few studies have examined racial/ethnic differences in aspirin use for the prevention of cardiovascular disease (CVD).
Data from the 2001 Behavioral Risk Factor Surveillance System (n=2,514 African Americans; n=865 Hispanics; n=28,038 Whites) were used to assess racial/ethnic differences in aspirin use. Multivariable logistic regression was used to examine whether the likelihood of aspirin use differs by race/ethnicity after accounting for sociodemographic and CVD risk factors.
Regular aspirin use was associated with increasing age, male gender, lower educational attainment, hypertension, diabetes, overweight, and histories of myocardial infarction, coronary heart disease, and stroke. Aspirin use was lower among African Americans and Hispanics than Whites (28.6% and 28.7% vs 37.1%, respectively). After adjustment for sociodemographic and CVD risk factors, African Americans and Hispanics were 30%-40% less likely than Whites (OR=0.6, 95% C1=0.5, 0.7, African Americans; OR=0.7, 95% CI=0.5, 1.0, Hispanics) to take aspirin. Although aspirin use was higher among those with CVD (73.6% African Americans, 73.6% Hispanics, and 82.7% Whites), after multivariable adjustment, African Americans and Hispanics with CVD remained 30% to 50% less likely to use aspirin than Whites (OR=0.7, 95% CI=0.4, 1.2, African Americans; OR=0.5, 95% CI=0.2, 1.1, Hispanics).
African Americans and Hispanics are less likely to take aspirin than their White counterparts. Differences in sociodemographic characteristics and CVD risk factors do not account for lower aspirin use among racial/ethnic minorities. Additional studies should examine methods to increase aspirin use in these populations.
定期服用阿司匹林，尤其是作为二级预防措施，可降低心脏病和中风的发病率。很少有研究探讨在预防心血管疾病（CVD）方面阿司匹林使用的种族/民族差异。
使用2001年行为危险因素监测系统的数据（n = 2514名非裔美国人；n = 865名西班牙裔；n = 28038名白人）来评估阿司匹林使用的种族/民族差异。多变量逻辑回归用于检验在考虑社会人口统计学和CVD危险因素后，阿司匹林使用的可能性是否因种族/民族而异。
定期服用阿司匹林与年龄增长、男性、教育程度较低、高血压、糖尿病、超重以及心肌梗死、冠心病和中风病史有关。非裔美国人和西班牙裔的阿司匹林使用率低于白人（分别为28.6%和28.7%，而白人是37.1%）。在调整社会人口统计学和CVD危险因素后，非裔美国人和西班牙裔服用阿司匹林的可能性比白人低30%-40%（非裔美国人的OR = 0.6，95%CI = 0.5，0.7；西班牙裔的OR = 0.7，95%CI = 0.5，1.0）。尽管患有CVD者的阿司匹林使用率较高（非裔美国人73.6%，西班牙裔73.6%，白人82.7%），但经过多变量调整后，患有CVD的非裔美国人和西班牙裔使用阿司匹林的可能性仍比白人低30%至50%（非裔美国人的OR = 0.7，95%CI = 0.4，1.2；西班牙裔的OR = 0.5，95%CI = 0.2，1.1）。
非裔美国人和西班牙裔服用阿司匹林的可能性低于白人。社会人口统计学特征和CVD危险因素的差异并不能解释种族/民族少数群体阿司匹林使用率较低的原因。更多研究应探讨提高这些人群阿司匹林使用率的方法。
